Carlyle Group Inc. E Ffector Therapeutics, Inc. Transaction History
Carlyle Group Inc.
- $837 Million
- Q2 2024
Shares
1 transactions
Others Institutions Holding EFTR
# of Institutions
6Shares Held
6.53MCall Options Held
0Put Options Held
0-
Abingworth LLP London, X04.82MShares$00.69% of portfolio
-
Oup Management Co., LLC1.03MShares$01.38% of portfolio
-
Evolution Capital Management LLC Crystal Bay, NV528KShares$01.04% of portfolio
-
Parallel Advisors, LLC67.7KShares$00.0% of portfolio
-
Blackstone Inc New York, NY52.3KShares$00.0% of portfolio
About eFFECTOR Therapeutics, Inc.
- Ticker EFTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,452,800
- Description
- eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...